Advancing Health.
Transforming Lives.
Made Better.
Brains Bioceutical owns the infrastructure, regulatory approvals, and partnerships that will define a $200 billion cannabinoid market transformation. With EU-GMP certification, 30+ clinical trials supported, and 500+ commercial batches produced, Brains Bio isn’t preparing for this transformation, we’re leading it.
Four Strategic Pillars. Exponential Returns.
The cannabinoid market represents one of the most significant pharmaceutical opportunities of the next decade. Our synergistic model creates compound value: APIs drive therapeutic development, therapeutics validate nutraceutical applications, and our manufacturing excellence enables it all. Each pillar reinforces the others, creating an unstoppable momentum toward market leadership.
Brains Bio API
Pharmaceuticals
Nutraceuticals
Animal Health
State-of-the-art EU GMP Manufacturing Capabilities
View the facility tour
Brains Bio API
The Pharmaceutical APIs Market is Expected to Exceed $50 Billion by 2025.
Brains Bio operates the world's only EU-GMP certified cannabinoid manufacturing facility at scale, producing pharmaceutical-grade APIs including CBD, D9-THC, D8-THC, CBN, and CBG for industry leading multinationals. Our diversified cannabinoid platform has supported 30+ clinical trials and 500+ commercial GMP batches with industry-leading purity standards, positioning us to become the first globally market-authorized cannabinoid API supplier upon approval in Brazil. The API division is anchored by a substantial contracted revenue pipeline and regulatory advantages that would take competitors years to replicate.
Pharmaceuticals
Targeting the Multi-Billion Dollar Therapeutic Markets
Brains Bio's pharmaceutical pipeline strategically targets high-value indications with significant unmet medical needs, leveraging our EU-GMP manufacturing platform and proprietary formulations to advance cannabinoid therapeutics from clinical development to commercialization. Our disciplined approach spans opioid use disorder programs, the potential first globally market-authorized CBD pharmaceuticals in Brazil, and novel formulations addressing sleep disorders and glaucoma with clear regulatory pathways. Each program creates synergistic value by driving API demand while generating high-margin revenue streams through licensing partnerships and direct commercialization opportunities.
Identify and Advance High-Impact Product Candidates
In-License and Co-Develop with Leading R&D Partners
Comprehensive Development and Regulatory Excellence
Nutraceuticals
First-Mover Advantage in Regulated Wellness Markets
Brains Bio's nutraceuticals division leverages pharmaceutical-grade manufacturing to capture value in the expanding regulated wellness market, with UK Novel Foods approval secured and EU EFSA submission underway creating defensible competitive advantages. Our strategic partnership with Vitabiotics, the UK's leading vitamin company, validates our approach while our multi-tiered brand architecture spans premium positioning at Harrods to mass market presence across major retail chains. The division benefits from regulatory barriers that few competitors can meet, positioning us for first-wave market expansion as global wellness regulations favor pharmaceutical-grade quality standards.
